Sen­a­tors call on FDA to not risk bi­as­ing study find­ings in fa­vor of opi­oid use

De­mo­c­rat Sens. Ed Markey of Mass­a­chu­setts and Joe Manchin of West Vir­ginia are call­ing on FDA Com­mis­sion­er Rob Califf not to per­mit the use of en­riched en­roll­ment ran­dom­ized with­draw­al (EERW) re­search to de­ter­mine the long-term ef­fi­ca­cy and tol­er­a­bil­i­ty of opi­oids in chron­ic pain pa­tients.

The let­ter ex­plains how such EERW re­search can bias opi­oids in fa­vor of ap­proval and un­der­es­ti­mate their ad­verse ef­fects as of­ten­times par­tic­i­pants who do not tol­er­ate the neg­a­tive side ef­fects of the opi­oids do not move in­to the dou­ble-blind por­tion of the tri­al and do not af­fect the re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER